Immune Pharmaceuticals Announces Adjournment of Annual Meeting of Stockholders and Provides Business Update

  • 5 of 6 proposals pass with shareholder approval
  • Meeting adjourned solely with respect to Proposal 4 - Ratification of the Reverse Stock Split
  • Company outlines key corporate and clinical milestones for 2018 


Immune Pharmaceuticals to Present at the BIO CEO & Investor Conference on February 12, 2018

Immune Pharmaceuticals Inc. (NASDAQ First North: IMNP) a biopharmaceutical company developing novel therapeutic agents for the treatment of immunologic and inflammatory diseases, announced that its CEO, Elliot Maza, will present at the BIO CEO & Investor Conference, to be held February 12-13 at the New York Marriott Marquis in New York, NY.


Immune Pharmaceuticals Announces Adjournment of Annual Meeting

Annual Meeting to Resume Thursday, February 15, 2018


Immune Pharmaceuticals to Present at the NobleCon 14 Annual Investor Conference on January 30, 2018

Immune Pharmaceuticals Inc. (NASDAQ: IMNP) a biopharmaceutical company developing novel therapeutic agents for the treatment of immunologic and inflammatory diseases, announced that its CEO, Elliot Maza, will present at NobleCon14- Noble Capital Markets' Fourteenth Annual Investor Conference, to be held January 29-30 at the W Hotel in Fort Lauderdale, Florida.


Immune Pharmaceuticals Announces Acceptance of Late-Breaking Abstract at the American Academy of Dermatology Annual Meeting 2018

Oral Presentation to Include Positive Interim Results from its Ongoing Phase 2 Trial of Bertilimumab in Bullous Pemphigoid


Immune Pharmaceuticals to Present at the Biotech Showcase™ Annual Conference on January 10, 2018

Immune Pharmaceuticals Inc. (NASDAQ: IMNP), a biopharmaceutical company developing novel therapeutic agents for the treatment of immunologic and inflammatory diseases, announced that it will present at Biotech Showcase ™ 2018, to be held January 8-10 during the most important week in healthcare investment forums at the Hilton San Francisco Union Square.


Notice to attend the Annual General Meeting of Shareholders of Immune Pharmaceuticals

The shareholders of Immune Pharamceuticals, Inc. (First North: IMNP), (the "Company") are hereby convened to the 2017 Annual General Meeting (the "AGM") to be held on Thursday, 25 January 2018 at 4:00 PM Central European Time (CET) at the offices of Nixon Peabody LLP, 55 West 46th Street, New York, New York 10036. 


Immune Pharmaceuticals Announces Change in Certifying Accountant

Immune Pharmaceuticals Inc. (NASDAQ First North: IMNP) (the "Company") a biopharmaceutical company developing novel therapeutic agents for the treatment of immunologic and inflammatory diseases, announced that the Audit Committee of the Company notified BDO USA, LLP ("BDO") the Company's independent registered public accounting firm for the fiscal year ending December 31, 2017, that the Company and its Audit Committee had determined to dismiss BDO effective as of December 7, 2017. On and effective as of December 7, 2017, the Company entered into an engagement letter with Marcum, LLP ("Marcum") as approved by the Audit Committee, and engaged Marcum to act as the Company's independent registered public accounting firm.


Immune Pharmaceuticals Announces 2017 Annual Shareholder Meeting

Englewood Cliffs, NJ, USA - December 13, 2017 - Immune Pharmaceuticals Inc. (NASDAQ First North: IMNP) (the "Company") a biopharmaceutical company developing novel therapeutic agents for the treatment of immunologic and inflammatory diseases, announced that the Company filed a preliminary proxy statement with the United States Securities and Exchange Commission ("SEC") on December 8, 2017 in connection with the Company's 2017 Annual Meeting of Stockholders, which is proposed to be held on January 25, 2018. The SEC review period for filings of this type customarily are ten (10) calendar days, but may be longer in the discretion of the SEC. The formal Notice of Annual Meeting and a definitive proxy statement more fully describing the purposes of the Annual Meeting will be distributed to all stockholders later this month following completion of the SEC approval process.


Följ oss

Om beQuoted

beQuoted publicerar nyheter, analyser och pressmeddelanden för investerare och journalister. Viktiga företagshändelser bevakas av vår egen nyhetsredaktion och vidaredistribueras i ledande finansiella medier.

Vi uppdaterar även nyhetsrum, Investor Relations och IR-webbplatser för företag som vill utveckla sina relationer med finansmarknaden.

Kontakta oss

beQuoted AB
Sturegatan 32
114 36 Stockholm

08-692 21 90
Kontaktformulär

Kontakta oss

Vill du veta mer om beQuoted och våra tjänster så fyll i nedanstånde uppgifter och tryck skicka.

En av våra rådgivare kontaktar dig inom kort.

Namn: Telefon: E-postadress: Meddelande: